PubblicazioniPublications    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   HomePubblicazioni
Pubblicazioni IGM

The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: Implications for drug design.

Autori

Kissova M, Maga G, Crespan E.

Riferimenti

BIOORGANIC & MEDICINAL CHEMISTRY 24(19) 4555-4532, 2016

Autori CNR

CRESPAN, MAGA

Moduli

Abstract

The tyrosine kinase Kit, a receptor for Stem Cell Factor, is involved, among others, in processes associated to cell survival, proliferation and migration. Upon physiological conditions, the activity of Kit is tightly regulated. However, primary mutations that lead to its constitutive activation are the causal oncogenic driver of gastrointestinal stromal tumours (GISTs). GISTs are known to be refractory to conventional therapies but the introduction of Imatinib, a selective inhibitor of tyrosine kinases Abl and Kit, significantly ameliorated the treatment options of GISTs patients. However, the acquisition of secondary mutations renders Kit resistant towards all available drugs. Mutation involving gatekeeper residues (such as V654a and T670I) influence both the structure and the catalytic activity of the enzyme. Therefore, detailed knowledge of the enzymatic properties of the mutant forms, in comparison with the wild type enzyme, is an important pre-requisite for the rational development of specific inhibitors. In this paper we report a thorough kinetic analysis of the reaction catalyzed by the Kit kinase and its gatekeeper mutated form T670I. Our results revealed the different mechanisms of action of these two enzymes and may open a new avenue for the future design of specific Kit inhibitors.

Link all articolo

http://www.sciencedirect.com/science/article/pii/S0968089616305806

Parole Chiave

Note

10.1016/j.bmc.2016.07.059

Indietro


Copyright © 2014 Home